Atrial Fibrillation and Cancer: a Nationwide French Cohort Study

September 29, 2022 updated by: Joachim ALEXANDRE, University Hospital, Caen

Atrial fibrillation (AF) is a common complication associated with cancer but the risk of AF according to the cancer localization and status as well as the risk of thromboembolisms, bleedings and mortality are poorly known.

The objective of this study is to use a very large French nationwide cohort to adress thèses questions.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Other: event occurence

Study Type

Observational

Enrollment (Anticipated)

5000000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

France
- - Tours, France, 37000
    - Service de Cardiologie, Centre Hospitalier Universitaire Trousseau

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients hospitalized from january 2010 to december 2019 and having an available ICD-10 code discharge.

Description

Inclusion Criteria:

adult hospitalized patients
with an ICD-10 code discharge from january 2010 to december 2019 in the French national hospital discharge database (PMSI Programme de Médicalisation des Systèmes d'Information)

Exclusion Criteria:

children

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
atrial fibrillation Time Frame: from inclusion in the cohort up to 10 years	occurrence of atrial fibrillation	from inclusion in the cohort up to 10 years
cancer Time Frame: ffrom inclusion in the cohort up to 10 years	occurrence of cancer	ffrom inclusion in the cohort up to 10 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
thromboembolism Time Frame: from inclusion in the cohort up to 10 years	occurrence of thromboembolism	from inclusion in the cohort up to 10 years
bleeding Time Frame: from inclusion in the cohort up to 10 years	occurrence of bleeding	from inclusion in the cohort up to 10 years
mortality Time Frame: from inclusion in the cohort up to 10 years	occurrence of mortality	from inclusion in the cohort up to 10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Caen

Collaborators

University Hospital, Tours

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 22, 2022

Primary Completion (Anticipated)

January 1, 2030

Study Completion (Anticipated)

January 1, 2030

Study Registration Dates

First Submitted

September 24, 2022

First Submitted That Met QC Criteria

September 29, 2022

First Posted (Actual)

October 3, 2022

Study Record Updates

Last Update Posted (Actual)